Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Journal of Drugs in Dermatology : JDD|October 5, 2019
Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled TrialsMark G. Lebwohl, Jeffrey L. Sugarman, Linda Stein Gold, et al.The American Journal of Gastroenterology|July 18, 2023
P029 Pharmacokinetic/Pharmacodynamic Analysis of Amiselimod, a Selective Sphingosine 1-Phosphate Receptor Modulator, in Healthy Subjects: Results From a Phase 1 StudyJimin Lee, Robert Lester, Terry O'Reilly, et al.Cureus|February 12, 2024
Dermal Granuloma Annulare After SARS-CoV-2 Vaccination: A Rare ComplicationMuhammad Tahir, Belin F Bodies, Sara Shalin, et al.Vaccine|December 19, 2012
A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancerSusan F Slovin, Marissa Kehoe, Robert Durso, et al.Journal of Drugs in Dermatology : JDD|October 27, 2018
Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled TrialsLawrence J Green, Francisco A Kerdel, Fran E Cook-Bolden, et al.Journal of the American Academy of Dermatology|April 4, 2018
Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trialsLinda Stein Gold, Mark G Lebwohl, Jeffrey L Sugarman, et al.Journal of Drugs in Dermatology : JDD|August 21, 2018
Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 StudiesJeffrey L Sugarman, Jonathan Weiss, Emil A Tanghetti, et al.The Journal of Supportive Oncology|March 13, 2009
Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patientsNeal Slatkin, Jay Thomas, Arthur G Lipman, et al.Pageof 1